Pentoxifylline potentiates in vitro lymphocyte suppression by glucocorticoids and immunosuppressive drugs

Journal of Clinical Pharmacology

Volumn 38, Issue 6, 1998, Pages 561-566

  Briggs, William A ^a   Eustace, Joseph ^a   Mathew, Suresh ^a   Gimenez, Luis F ^a   Choi, Michael ^a   Scheel Jr , Paul J ^a   Burdick, James ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PENTOXIFYLLINE; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ARTICLE; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; TREATMENT OUTCOME;

EID: 0031802279     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb05795.x     Document Type: Article

References (21)

1. Schandene L, Vandenbussche P, Crusiaux A, Alegre AL, Abramowicz D, Dupont E, et al: Differential effects of pentoxifylline in the production of tumor necrosis factor-alpha and interleukin-6 by moncytes and T cells. Immunology 1992;76:30-34.
2. Reed WR, DeGowin RL: Suppressive effects of pentoxifylline on natural killer cell activity. J Lab Clin Med 1992;119:763-771.
3. Tilg H, Eibl B, Pichl M, Gachter A, Herold M, Brankova J, et al: Immune response modulation by pentoxifylline in vitro. Transplantation 1993;56:196-201.
4. Thanhauser A, Reiling N, Bohle A, Toellner KM, Dunchrow M, Scheel D, et al: Pentoxifylline: a potent inhibitor of IL-2 and IFN-γ biosynthesis and BCG-induced cytotoxicity. Immunology 1993; 80:151-156.
5. Semmler J, Gebert U, Eisenhut T, Moeller J, Schonharting MM, Allera A, et al: Xanthine derivatives: comparison between suppression of tumor necrosis factor α production and inhibition of cAMP phosphodiesterase activity. Immunology 1993;78:520-525.
6. Rieneck K, Diamant M, Haahr PM, Schonharting M, Bendtzen K: In vitro immunomodulatory effects of pentoxifylline. Immunol Lett 1993;37:131-138.
7. Bienvenu J, Doche C, Gutowski M, Lenoble M, Lepape A, Perdrix J: Production of proinflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. J Cardiovasc Pharmacol 1995;25(Suppl 2):S80-S84.
8. Benbernou N, Esnault S, Potron C, Guenounou M: Regulatory effects of pentoxifylline on T helper cell-derived cytokine production in human blood cells. J Cardiovasc Pharmacol 1995;25(Suppl 2):S75-S79.
9. Funk JO, Ernest M, Schonharting MM, Zabel P: Pentoxifylline exerts synergistic immunomudulatory effects in combination with dexamethasone or cyclosporine A. Int J Immunopharmacol 1995;17:1007-1016.
10. Khabar SK, Dzimiri M, Parhar RS, Siddiqui S, Einspenner M, Al-Humaidan A, et al: Pentoxifylline selectively potentiates cyclosporine mediated suppression of cell mediated lymphocytoxicity. Transplantation 1996;61:838-841.
11. Hoskin DW, Phu T, Makrigiannes P: Pentoxifylline inhibits granzyme B and perforin expression following T-lymphocyte activation by anti-CD3 antibody. Int J Immunopharmacol 1996;18: 623-631.
12. Briggs WA, Gao Z-H, Gimenez LF, Scheel PJ Jr., Choi MJ, Burdick JF: Lymphocyte responsiveness to glucocorticoids, cyclosporine, or both. J Clin Pharmacol 1996;36:707-714.
13. Neuner P, Klosner G, Schauer E, Pourmojib M, Macheiner W, Grunwald C, et al: Pentoxifylline in vivo down-regulates the release of IL-1β, IL-6, IL-8 and tumor necrosis factor α by human peripheral blood mononuclear cells. Immunology 1994;83:262-267.
14. Kammer GM: The adenylate cyclase protein kinase A pathway and regulation of the immune response. Immunol Today 1988;9:222-229.
15. Hutchinson IV: Immune mechanisms of long-term graft acceptance. Adv Nephrol Necker Hosp 1996;25:17-38.
16. Beermann B, Ings R, Mansby J, Chamberlain J, McDonald A: Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clin Pharmacol Ther 1985;37:25-28.
17. Dezube BJ, Sherman AL, Fridovich-Keil JL, Allen-Ryan J, Pardee AB: Down-regulation of tumour necrosis factor expression by pentoxifylline in cancer patients: a pilot study. Cancer Immunol Immunother 1993;36:57-60.
18. Dezube BJ, Lederman MM: Pentoxifylline for the treatment of HIV infection and its complications. J Cardiovasc Pharmacol 1995;25(Suppl 2):S139-S142.
19. Neuner P, Klosner G, Pourmojib M, Knobler R, Schwartz T: Pentoxifylline in vivo and in vitro down-regulates the expression of the intercellular adhesion molecule-1 in monocytes. Immunology 1997;90:435-439.
20. Maksymowych WP, Avina-Zubieta A, Luong MH, Russell AS: An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J Rheumatol 1995;22:625-629.
21. Yasui K, Ohta K, Kobayashi M, Aizawa T, Komiyama A: Successful treatment of Behcet disease with pentoxifylline. Ann Intern Med 1996;124:891-893.